Valiant Laboratories logo

Valiant Laboratories financials: balance sheet, profit and loss, cash flow

NSE: VALIANTLABBSE: 543998Pharmaceuticals & BiotechnologySmall Cap

Valiant Laboratories Limited · Face value ₹10 · Listed Oct 2023 · Issue price ₹140
Last close ₹125.82up ₹2.46 (1.99%)BSE ₹126.65

Share price at the NSE close on 28 Oct 2026. Previous close ₹123.36.

28 Oct: open ₹120.91, high ₹125.82, low ₹120.90

52-week range of traded prices to 27 Oct 2026
₹49.51Low, 4 Mar 2026₹141.38High, 19 Oct 2026
Market cap
₹670 Cr2,048th largest listed
P/E
41.86
P/B
2.16
Dividend yield
Nonein the last 12 months
ROE
5.9%
ROCE
7.0%
Debt to equity
0.14
Volume, NSE
86,797

Valiant Laboratories' financial statements for the 3 years to Mar 2026, consolidated: the company and its subsidiaries together, with the twelve months to Jun 2026 after them.

3 years at a glance

₹ crore, years to March.Valiant Laboratories annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
1820.376Mar 24133−2.2121Mar 25237−3.345Mar 26
Peak revenue ₹237 Cr, year to Mar 2026; lowest ₹133 Cr, year to Mar 2025A loss in 2 of the 3 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin
2.7%−4.6%−4.6%−3.5%2.7%0.2%−1.7%−1.4%Mar 24Mar 25Mar 26

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue237
  2. Materials and goods−197
  3. Employee costs−7.0
  4. Other expenses−27
  5. Operating profit6.4
  6. Depreciation−6.0
  7. Other income+2.3
  8. One-off items0.0
  9. Finance costs−1.9
  10. Profit before tax0.8
  11. Tax−4.0
  12. Net profit−3.3

What the company owns

  • Plant, investments and other assets₹292 Cr
  • Receivables₹94 Cr
  • Inventory₹45 Cr
  • Current investments₹26 Cr
  • Cash and bank₹7 Cr

What pays for it: net worth and liabilities

  • Net worth₹311 Cr
  • Owed to suppliers₹94 Cr
  • Borrowings₹45 Cr
  • Other liabilities₹14 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Valiant Laboratories quarterly results

₹ croreMar 2024Mar 2025Mar 2026Jun 2026Twelve monthsFiled 10 Aug
Revenue from operations182133237306
190138231273
Materials and goods bought168117197225
Employee costs4478
Other expenses18172739
Operating profit before depreciation−8−5633
Operating margin−4.6%−3.5%2.7%10.9%
Materials, % of revenue92.4%87.4%83.0%73.6%
Employee costs, % of revenue2.4%3.3%2.9%2.7%
Other expenses, % of revenue9.8%12.8%11.3%12.8%
Depreciation and amortisation2268
Operating profit after depreciation−10−7025
Other income10523
Finance costs0023
One-off items0000
Profit before tax−1−2125
−1149
0−2−316
Other comprehensive income0000
Total comprehensive income0−2−316
Net margin0.2%−1.7%−1.4%5.2%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2024Mar 2025Mar 2026
237234311
Share capital434354
Reserves193191257
7612145
2960119
7710734
Total assets343401464
117208236
226193228
Net debt−684512
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2024Mar 2025Mar 2026
21−10
1−1−9
0−4−17
Receivables43−27−21
Inventories36−41
Payables−211553
Other working capital−253−8
Tax paid12−1
Capital spending4611434
Free cash flow−44−113−45
−144−537
152452
Dividends paid000
Shares bought back000
Shares issued136011
Net change in cash10−7−1
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.

₹ per shareMar 2024Mar 2025Mar 2026
Earnings per share₹0.13−₹0.51−₹0.51
Diluted earnings per share₹0.13−₹0.51−₹0.51
Book value per share₹54.51₹53.93₹57.24
Shareholder yield−21.6%0.0%−3.9%
Market cap at the year end (₹ crore)630333280

Ratios

Consolidated, years to March.Valiant Laboratories PE ratio and valuation

RatioMar 2024Mar 2025Mar 2026
Revenue growth–−26.7%78.0%
0.1%−0.9%−1.2%
–−1.1 pts−0.3 pts
From the net margin–−1.4 pts0.2 pts
From asset turnover–0.4 pts−0.4 pts
From borrowing–−0.1 pts0.0 pts
Return on capital employed−3.3%−1.9%0.1%
Cash conversion589.9%––
Interest cover––0.2
Debt to equity0.320.520.14
Receivable days92197144
Inventory days221284
Payable days56127174
Cash conversion cycle, days578254
Working capital days108202142
Asset turnover0.530.360.55
Assets per rupee of net worth1.451.581.59
Sales per rupee of plant3.642.761.05
Capital spending to depreciation23.3454.415.66
Plant being built, % of plant in use85.2%322.3%2.7%
Interest cover is left blank for the years to Mar 2024 and Mar 2025: operating profit after depreciation is a loss, and a loss covers no interest bill.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
−0.8%
Cash from operations against operating profit
−163.3%
Measure3 years
Return on equity, average−0.7%
Return on capital employed, average−1.7%
Operating margin, average−1.8%
Net margin, average−1.0%
Asset turnover, average0.48
Cash conversion cycle, days, average64
Debt to equity, average0.33

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore3 yearsLatest year
Cash from operations−7−10
Cash from investing−1897
Cash from financing1992
Capital spending19434
Dividends paid00
Shares bought back00
Shares issued for cash14711
Borrowings raised620
Borrowings repaid7676

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––3
Altman Z-scorePublished threshold 1.815.582.592.69
Beneish M-scorePublished threshold −1.78–−1.71−2.32
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–13.25−0.02
Receivables growth less revenue growthOur threshold 0 percentage points–84.46−48.30
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–−29.47969.78
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–10.886.61
Assets under construction, years of additionsOur threshold 2 years of additions–423.430.03
Effective tax ratePublished threshold 17.16 per cent––525.40
Tax charged less tax paid, % of profitOur threshold 10 percentage points––393.89
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
3 Sep 2026India Ratings and Research Private LimitedBank loan facilitiesIND BBB; IND A2Review, Re-affirmStable56
30 Jun 2026CRISIL Ratings LimitedBank FacilitiesCrisil BB(Issuer Not Cooperating)Review, OtherStable50
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.